One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
3-Year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma
S.CedresE.Felip
FIGHT against FGF/FGFR alterations: what are the next steps?
A.BayleP.Martin-RomanoY.Loriot
‘Rare cancers’: not all together in clinical studies!
P.G.Casali12L.Licitra32A.M.Frezza1A.Trama4
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
A.Passaro1N.Leighl†2†F.Blackhall†34†S.Popat†567†K.Kerr†8†M.J.Ahn9M.E.Arcila10O.Arrieta11D.Planchard12F.de Marinis1A.M.Dingemans13R.Dziadziuszko14C.Faivre-Finn15J.Feldman16E.Felip17G.Curigliano18R.Herbst19P.A.Jänne20…S.Peters35
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
S.Peters1A.Scherpereel2R.Cornelissen3Y.Oulkhouir4L.Greillier5M.A.Kaplan6T.Talbot7I.Monnet8S.Hiret9P.Baas10A.K.Nowak11N.Fujimoto12A.S.Tsao13A.S.Mansfield14S.Popat1516X.Zhang17N.Hu18D.Balli19…G.Zalcman21
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
D.Gale12‡K.Heider12‡A.Ruiz-Valdepenas12‡S.Hackinger3M.Perry3G.Marsico3V.Rundell4J.Wulff4G.Sharma3H.Knock4J.Castedo25W.Cooper12H.Zhao12C.G.Smith12S.Garg6S.Anand6K.Howarth3D.Gilligan57…N.Rosenfeld123§
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data
M.Pérol1†E.Felip2†U.Dafni34L.Polito5N.Pal6Z.Tsourti4T.G.N.Ton6D.Merritt7S.Morris7R.Stahel8‡S.Peters9‡
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
V.Subbiah1N.O.Iannotti2M.Gutierrez3D.C.Smith4L.Féliz5C.F.Lihou6C.Tian6I.M.Silverman6T.Ji6M.Saleh78
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
L.Gianni1C.S.Huang2D.Egle3B.Bermejo4C.Zamagni5M.Thill6A.Anton7S.Zambelli8G.Bianchini8S.Russo9E.M.Ciruelos10R.Greil111213V.Semiglazov14M.Colleoni15C.Kelly16G.Mariani17L.Del Mastro1819I.Maffeis1…G.Viale1520
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma
C.Robert1K.D.Lewis2R.Gutzmer3D.Stroyakovskiy4H.Gogas5S.Protsenko6R.P.Pereira7T.Eigentler8P.Rutkowski9L.Demidov10I.Caro11H.Forbes12K.Shah11Y.Yan11H.Li12G.A.McArthur13†P.A.Ascierto14â€
Paradigms for the development of transformative medicines—lessons from the EGFR story
W.PaoY.A.Nagel
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
M.MoschiniG.GandagliaF.DehòA.SaloniaA.BrigantiF.Montorsi
Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program
F.Y.-V.Pham12E.Jacquet3A.Monard14L.Brunel1J.-Y.Blay5N.Albin14
Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer
V.Di Noia1F.Pimpinelli2D.Renna1M.T.Maccallini2L.Gariazzo2F.Riva2E.Sperandio3D.Giannarelli3F.Cognetti14
VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
A.N.J.Tutt1J.Garber2R.D.Gelber2K-A.Phillips3A.Eisen4O.T.Johannsson5P.Rastogi6K.Y.Cui7S-A.Im8R.Yerushalmi9A.M.Brufsky10M.Taboada11G.Rossi12G.Yothers13C.Singer14L.E.Fein15N.Loman16D.Cameron17…C.E.Geyer19
